Health Care & Life Sciences » Biotechnology | EPIRUS Biopharmaceuticals Inc.

EPIRUS Biopharmaceuticals Inc. | Income Statement

Fiscal year is January-December. All values USD Thousands.
2011
2012
2013
2014
2015
Sales/Revenue
8,184.00
12,550.00
14,731.00
4.00
701.00
Cost of Goods Sold (COGS) incl. D&A
40,435.00
-
-
-
722.00
Gross Income
32,251.00
-
-
-
21.00
SG&A Expense
10,400.00
48,919.00
40,161.00
32,944.00
46,235.00
EBIT
42,651.00
41,742.00
35,478.00
33,105.00
46,256.00
Unusual Expense
-
1,094.00
1,732.00
6,350.00
6,044.00
Non Operating Income/Expense
20.00
91.00
14.00
240.00
900.00
Interest Expense
976.00
2,173.00
1,467.00
2,672.00
1,332.00
Pretax Income
43,471.00
44,768.00
38,617.00
41,887.00
52,732.00
Income Tax
1,428.00
441.00
-
43.00
544.00
Consolidated Net Income
42,043.00
44,327.00
38,617.00
41,844.00
52,188.00
Net Income
42,043.00
44,327.00
38,617.00
41,844.00
52,188.00
Net Income After Extraordinaries
42,043.00
44,327.00
38,617.00
41,844.00
52,188.00
Net Income Available to Common
42,043.00
44,327.00
38,617.00
41,844.00
52,188.00
EPS (Basic)
25.80
22.67
16.84
6.81
2.29
Basic Shares Outstanding
1,622.50
1,955.30
2,293.30
6,141.60
22,747.80
EPS (Diluted)
25.91
22.67
16.84
6.81
2.29
Diluted Shares Outstanding
1,622.50
1,955.30
2,293.30
6,141.60
22,747.80
EBITDA
35,446.00
36,369.00
25,430.00
32,940.00
45,659.00
Non-Operating Interest Income
136.00
150.00
46.00
-
-

About EPIRUS Biopharmaceuticals

View Profile
Address
699 Boylston Street
Boston Massachusetts 02116
United States
Employees -
Website http://www.epirusbiopharma.com
Updated 07/08/2019
EPIRUS Biopharmaceuticals, Inc. is a biopharmaceutical company focused on building a pure-play, sustainable and profitable biosimilar business. It focuses on biosimilars, which are biologic drugs that are demonstrated to be highly similar to a previously approved biologic drug, known as a reference product. The company was founded on November 26, 2008 and is headquartered in Boston, MA.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.